These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

139 related articles for article (PubMed ID: 38101984)

  • 21. Stereotactic ablative radiotherapy as single treatment for early stage non-small cell lung cancer: A single institution analysis.
    Zheng X; Sun Y; Ye K; Fan C; Wang X; Yang Y; Jiao R; Ge H
    Thorac Cancer; 2021 Mar; 12(6):899-905. PubMed ID: 33529496
    [TBL] [Abstract][Full Text] [Related]  

  • 22. A comparison between accelerated hypofractionation and stereotactic ablative radiotherapy (SABR) for early-stage non-small cell lung cancer (NSCLC): Results of a propensity score-matched analysis.
    Chiang A; Thibault I; Warner A; Rodrigues G; Palma D; Soliman H; Jain S; Poon I; Cheung P
    Radiother Oncol; 2016 Mar; 118(3):478-84. PubMed ID: 26795773
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Clinical Outcomes of Stereotactic Ablative Radiotherapy for All Stages of Non-Small Cell Lung Cancer; Definitive versus Consolidative.
    Kim H; Kim SM; Yang DS; Lee KH; Kim YB
    Medicina (Kaunas); 2022 Sep; 58(9):. PubMed ID: 36143981
    [No Abstract]   [Full Text] [Related]  

  • 24. SUVmax Predicts Disease Progression after Stereotactic Ablative Radiotherapy in Stage I Non-small Cell Lung Cancer.
    Kwak YK; Park HH; Choi KH; Park EY; Sung SY; Lee SW; Hong JH; Lee HC; Yoo IR; Kim YS
    Cancer Res Treat; 2020 Jan; 52(1):85-97. PubMed ID: 31122008
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Stereotactic ablative radiotherapy versus lobectomy for operable stage I non-small-cell lung cancer: a pooled analysis of two randomised trials.
    Chang JY; Senan S; Paul MA; Mehran RJ; Louie AV; Balter P; Groen HJ; McRae SE; Widder J; Feng L; van den Borne BE; Munsell MF; Hurkmans C; Berry DA; van Werkhoven E; Kresl JJ; Dingemans AM; Dawood O; Haasbeek CJ; Carpenter LS; De Jaeger K; Komaki R; Slotman BJ; Smit EF; Roth JA
    Lancet Oncol; 2015 Jun; 16(6):630-7. PubMed ID: 25981812
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Consolidative Radiotherapy for Limited Metastatic Non-Small-Cell Lung Cancer: A Phase 2 Randomized Clinical Trial.
    Iyengar P; Wardak Z; Gerber DE; Tumati V; Ahn C; Hughes RS; Dowell JE; Cheedella N; Nedzi L; Westover KD; Pulipparacharuvil S; Choy H; Timmerman RD
    JAMA Oncol; 2018 Jan; 4(1):e173501. PubMed ID: 28973074
    [TBL] [Abstract][Full Text] [Related]  

  • 27. 7-year follow-up after stereotactic ablative radiotherapy for patients with stage I non-small cell lung cancer: Results of a phase 2 clinical trial.
    Sun B; Brooks ED; Komaki RU; Liao Z; Jeter MD; McAleer MF; Allen PK; Balter PA; Welsh JD; O'Reilly MS; Gomez D; Hahn SM; Roth JA; Mehran RJ; Heymach JV; Chang JY
    Cancer; 2017 Aug; 123(16):3031-3039. PubMed ID: 28346656
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Minimally invasive lobectomy versus stereotactic ablative radiotherapy for stage I non-small cell lung cancer.
    de Ruiter JC; van Diessen JNA; Smit EF; van der Noort V; Damhuis RAM; Hartemink KJ;
    Eur J Cardiothorac Surg; 2022 Aug; 62(3):. PubMed ID: 35348664
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Definitive Management of Presumed Synchronous Early Stage Non-Small Cell Lung Cancers: Outcomes and Utility of Stereotactic Ablative Radiation Therapy.
    Ayoub Z; Ning MS; Brooks ED; Kang J; Welsh JW; Chen A; Gandhi S; Heymach JV; Vaporciyan AA; Chang JY
    Int J Radiat Oncol Biol Phys; 2020 Jun; 107(2):261-269. PubMed ID: 32044413
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Stereotactic radiotherapy (SABR) for the treatment of primary non-small cell lung cancer; systematic review and comparison with a surgical cohort.
    Soldà F; Lodge M; Ashley S; Whitington A; Goldstraw P; Brada M
    Radiother Oncol; 2013 Oct; 109(1):1-7. PubMed ID: 24128806
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Circulating tumor DNA detection is correlated to histologic types in patients with early-stage non-small-cell lung cancer.
    Zhang B; Niu X; Zhang Q; Wang C; Liu B; Yue D; Li C; Giaccone G; Li S; Gao L; Zhang H; Wang J; Yang H; Wu R; Ni P; Wang C; Ye M; Liu W
    Lung Cancer; 2019 Aug; 134():108-116. PubMed ID: 31319968
    [TBL] [Abstract][Full Text] [Related]  

  • 32. SABRTooth: a randomised controlled feasibility study of stereotactic ablative radiotherapy (SABR) with surgery in patients with peripheral stage I nonsmall cell lung cancer considered to be at higher risk of complications from surgical resection.
    Franks KN; McParland L; Webster J; Baldwin DR; Sebag-Montefiore D; Evison M; Booton R; Faivre-Finn C; Naidu B; Ferguson J; Peedell C; Callister MEJ; Kennedy M; Hewison J; Bestall J; Gregory WM; Hall P; Collinson F; Olivier C; Naylor R; Bell S; Allen P; Sloss A; Snee M
    Eur Respir J; 2020 Nov; 56(5):. PubMed ID: 32616595
    [TBL] [Abstract][Full Text] [Related]  

  • 33. [Current Status of Stereotactic Ablative Radiotherapy (SABR) for Early-stage 
Non-small Cell Lung Cancer].
    Shi A; Zhu G
    Zhongguo Fei Ai Za Zhi; 2016 Jun; 19(6):389-93. PubMed ID: 27335303
    [TBL] [Abstract][Full Text] [Related]  

  • 34. When is a biopsy-proven diagnosis necessary before stereotactic ablative radiotherapy for lung cancer?: A decision analysis.
    Louie AV; Senan S; Patel P; Ferket BS; Lagerwaard FJ; Rodrigues GB; Salama JK; Kelsey C; Palma DA; Hunink MG
    Chest; 2014 Oct; 146(4):1021-1028. PubMed ID: 24853550
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Is stereotactic ablative radiotherapy equivalent to sublobar resection in high-risk surgical patients with stage I non-small-cell lung cancer?
    Mahmood S; Bilal H; Faivre-Finn C; Shah R
    Interact Cardiovasc Thorac Surg; 2013 Nov; 17(5):845-53. PubMed ID: 23900381
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Stereotactic ablative radiotherapy before resection to avoid delay for early-stage lung cancer or oligometastases during the COVID-19 pandemic: Pathologic outcomes from the SABR-BRIDGE protocol.
    Kidane B; Gerard IJ; Spicer J; Kim JO; Fiset PO; Wawryko P; Cecchini MJ; Inculet R; Abdulkarim B; Fortin D; Qiabi M; Qing G; Enns S; Bashir B; Tankel J; Wakeam E; Warner A; Kopek N; Yaremko BP; Rodrigues GB; Laba JM; Qu M; Malthaner RA; Palma DA
    Cancer; 2023 Sep; 129(18):2798-2807. PubMed ID: 37221679
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Stereotactic Ablative Radiation Therapy for the Treatment of Early-stage Non-Small-Cell Lung Cancer: CEPO Review and Recommendations.
    Boily G; Filion É; Rakovich G; Kopek N; Tremblay L; Samson B; Goulet S; Roy I;
    J Thorac Oncol; 2015 Jun; 10(6):872-82. PubMed ID: 26001140
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Stereotactic ablative radiotherapy (SABR) in early stage non-small cell lung cancer: Comparing survival outcomes in adenocarcinoma and squamous cell carcinoma.
    Abel S; Hasan S; White R; Schumacher L; Finley G; Colonias A; Wegner RE
    Lung Cancer; 2019 Feb; 128():127-133. PubMed ID: 30642444
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Contact of a tumour with the pleura is not associated with regional recurrence following stereotactic ablative radiotherapy for early stage non-small cell lung cancer.
    Wink KCJ; Löck S; Rossi M; van Baardwijk A; Belderbos J; de Ruysscher D; Troost EGC
    Radiother Oncol; 2019 Feb; 131():120-126. PubMed ID: 30773178
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Reirradiation of recurrent node-positive non-small cell lung cancer after previous stereotactic radiotherapy for stage I disease : A multi-institutional treatment recommendation.
    Nieder C; De Ruysscher D; Gaspar LE; Guckenberger M; Mehta MP; Cheung P; Sahgal A
    Strahlenther Onkol; 2017 Jul; 193(7):515-524. PubMed ID: 28424839
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 7.